Compare Ginkgo Bioworks Holdings Inc (DNA) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Microchip Technology Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.33 (market cap $505.73M), while Microchip Technology Inc. trades at $80.82 (market cap $43.99B). The key difference: Microchip Technology Inc. is far larger — about 87× Ginkgo Bioworks Holdings Inc's market cap, and Microchip Technology Inc. pays a 2.25% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MCHP | |
|---|---|---|
Market Cap | $505.73M | $43.99B |
Sector | Health | Technology |
52-Week High | $16.14 | $102.97 |
52-Week Low | $5.48 | $49.02 |
Enterprise Value | $607.68M | $49.12B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Microchip Technology (MCHP) trades at $81.39, down 3.9% on the day, amid a bullish technical setup and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.76 exceeding expectations. Recent news highlights robust data center revenue growth (98% last quarter) and strategic acquisitions like Hailo to bolster edge AI capabilities. Valuation metrics remain elevated with a P/E of 119.15, reflecting high growth expectations.
MCHP's outlook is positive with expanding AI infrastructure demand and raised guidance, though high valuation and recent net income pressure in 2025 pose risks. The consensus price target of $104 suggests 28% upside potential. Key risks include execution on growth initiatives and semiconductor cycle volatility. Institutional sentiment remains strongly bullish with no sell ratings among 44 analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
